Is Xarelto approved to prevent strokes in patients with Nonvalvular Atrial Fibrillation?
Xarelto (rivaroxaban) is a direct oral anticoagulant (DOAC) that is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). This approval was based on the landmark ROCKET-AF trial, which showed that rivaroxaban was noninferior to warfarin for preventing stroke or systemic embolism, with a similar or lower risk of major bleeding, especially intracranial hemorrhage. Clinical guidelines now recommend rivaroxaban as one of the preferred anticoagulants for NVAF.
What the research says
The ROCKET-AF trial, a large randomized controlled trial, established rivaroxaban as an effective alternative to warfarin for stroke prevention in NVAF 10. In that trial, the net clinical benefit (a composite of vascular death, stroke, myocardial infarction, fatal bleeding, critical organ bleeding, and non-CNS systemic embolism) favored rivaroxaban across all age groups, including patients over 75 years old 10. A network meta-analysis comparing DOACs and vitamin K antagonists (VKAs) found that rivaroxaban had a higher risk of intracranial hemorrhage compared to apixaban, but a lower risk than VKAs 4. In dialysis patients with AF, rivaroxaban and apixaban were associated with lower risks of major bleeding, gastrointestinal bleeding, and intracranial hemorrhage compared to VKAs 5. Another meta-analysis confirmed that standard-dose NOACs (including rivaroxaban) were the most effective for preventing stroke or systemic embolism, while low-dose NOACs were safest for major bleeding 2. Overall, rivaroxaban is a well-established option for stroke prevention in NVAF, with a benefit-risk profile that supports its use in appropriate patients.
What to ask your doctor
- Is rivaroxaban (Xarelto) a good option for me given my age, kidney function, and other health conditions?
- What dose of rivaroxaban would be appropriate for me, and do I need any dose adjustments?
- How does rivaroxaban compare to other DOACs like apixaban or edoxaban in terms of bleeding risk and effectiveness?
- Are there any specific foods or other medications I should avoid while taking rivaroxaban?
- What signs of bleeding should I watch for, and when should I seek medical attention?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.